PRAX News and Press, Praxis Precision Medicines Inc. From 05/11/21

Praxis Precision Medicines (PRAX) announces that it has commenced an underwritten public offering of 4M shares.Intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares.Praxis intends to use net proceeds, together with existing cash, for the advancem...

CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today...

Praxis Precision Medicines (PRAX): Q1 GAAP EPS of -$0.71 beats by $0.03.Cash, cash equivalents and marketable securities of $270.8M.Press Release For further details see: Praxis Precision Medicines EPS beats by $0.03

Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for treatment of essential tremor to initiate in 2H21 PRAX-944 Phase 2 trial for trea...

Gainers: Brooklyn ImmunoTherapeutics (BTX) +38%, Motus GI MOTS +32%, CryoLife (CRY) +16%, Mesoblast MESO +14%, Arcutis Biotherapeutics (ARQT) +10%.Losers: Ardelyx (ARDX) -13%, Pacific Biosciences of California (PACB) -13%, ALX Oncolo...

The FDA has granted Orphan Drug designation to Praxis Precision Medicines' (PRAX) PRAX-562 for the treatment of SCN2A development and epileptic encephalopathy (SCN2A-DEE).Earlier this month, PRAX-562 received the same designation for the treatment of SCN8A-DEE.The company plans to start a pha...

CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imba...

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, tod...

CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, tod...

Gainers: Cinedigm (CIDM) +20%.Grupo Televisa (TV) +20%.GameStop (GME) +18%.Nurix Therapeutics (NRIX) +18%.Centennial Resource Development (CDEV) +17%.Regulus Therapeutics (RGLS) +16%.NexImmune (NEXI) +16%.UP Fintech (TIGR) +16%.Kymera Therapeutics (KYMR) +15%.Transocean (RIG) +...